nach oben

Erschienen in:

01.01.2009 | Original Article

Survival analysis between patients with invasive ductal and invasive lobular breast cancer

verfasst von: Darius Dian, Hannes Herold, Ioannis Mylonas, Christoph Scholz, Wolfgang Janni, Harald Sommer, Klaus Friese

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

Differences in overall survival (OS) and disease-free survival (DFS) between patients with invasive ductal (IDC) and invasive lobular breast cancer (ILC) are controversial.

Study design

The study population was selected from a database of 5,689 female patients with invasive breast cancer. In order to focus on the impact of tumour histology, all primary metastatic patients and patients with adjuvant chemotherapy or anti-hormonal treatment were excluded. Only patients with pure invasive lobular and invasive ductal histology were included.

Results

Multivariate survival analyses of 2,058 eligible patients confirmed tumour histology as an independent prognostic factor for OS in invasive breast cancer (p = 0.046) but not for DFS (p = 0.599). Kaplan–Meier survival analysis of OS between IDC and ILC patients showed a statistically significantly better OS for patients with ILC (p = 0.0302). DFS was not statistically different (p = 0.6659) between IDC and ILC. Univariate survival analyses of tumour size, tumour grading and nodal status in our study population were highly statistically significant for OS and DFS (p < 0.0000).

Conclusion

Patients in our study population with ILC have significantly better OS than patients with IDC. Differences in DFS are not statistically significant.

Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424PubMedCrossRef

Martinez V, Azzopardi JG (1979) Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3:467–488PubMedCrossRef

Veronesi U, Salvadori B, Luini A, Banfi A, Zucali R, Del Vecchio M, Saccozzi R, Beretta E, Boracchi P, Farante G et al (1990) Conservative treatment of early breast cancer, long-term results of 1,232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 221:250–259

Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P (1996) Infiltrating lobular carcinoma of the breast clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77(1):113–120PubMedCrossRef

Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104(6):778–781PubMedCrossRef

Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95(12):2455–2464PubMedCrossRef

Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73:1673–1677PubMedCrossRef

Kurtz JM, Jaquemier J, Torhorst J, Spitalier JM, Amalric R, Hunig R, Walther E, Harder F, Almendra A, Brandone H et al (1989) Conservative therapy for breast cancers other than infiltrating duct carcinoma. Cancer 63(8):1630–1635PubMedCrossRef

Mate TP, Carter D, Fischer DB, Hartman PV, McKhann C, Merino M, Prosnitz LR, Weissberg JB (1986) A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer 58:1995–2002PubMedCrossRef

10.

Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannapopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG (2004) Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer. Anticancer Res 24(3b):2061–2068

11.

Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 163(18):2149–2153PubMedCrossRef

12.

Fondrinier E, Guerin O, Lorimier G (1997) A comparison of metastatic patterns of invasive ductal and lobular carcinomas of the breast: result of a matched study. Bull Cancer 84:1101–1107PubMed

13.

Winchester DJ, Mencj HR, Winchester DP (1997) The National Cancer Data Base Report on the results of a large non-randomised comparison of breast preservation and modified radical mastectomy. Cancer 80:162–167PubMedCrossRef

14.

Salvadori B, Biganzoli E, Veronesi P, Saccozzi R, Rilke F (1997) Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg 84:106–109PubMedCrossRef

15.

Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR (1997) Optimal surgical treatment of invasive lobular carcinoma. Ann Surg Oncol 4(7):545–550PubMedCrossRef

16.

Arpino G, Bardou V, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156PubMedCrossRef

17.

Molland JG, Donnellan M, Janu NC, Carmalt HL, Kenneddy CW, Gillett DJ (2004) Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 13:389–396PubMedCrossRef

18.

Korhonen T, Huhtala K, Holli K (2004) A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Res Treat 85:23–29PubMedCrossRef

19.

Santiago RJ, Harris EE, Quin L, Hwang WT, Solin LJ (2005) Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: the University of Pennsylvania experience. Cancer 103(12):2447–2454PubMedCrossRef

20.

Mersin H, Yildrim E, Gulben K, Berberoglou U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29(4):390–395PubMedCrossRef

21.

du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JF, Blamey RW (1992) An evaluation of difference in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17:251–257

22.

Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457–481CrossRef

23.

Peiro G, Bornstein BA, Connolly JL, Gelman R, Heteledekidis S, Nixon AJ, Recht A, Silver B, Harris JR, Schnitt SJ (2000) The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 59:49–54PubMedCrossRef

24.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41–48PubMedCrossRef

25.

Coquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal carcinoma. Eur J Surg Oncol 29:361–367CrossRef

26.

Li Cl, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052PubMedCrossRef

27.

Jalava P, Kuopio T, Huovinen R, Laine J, Collan Y (2005) Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 25(3c):35–42

28.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P (2005) Correlation of her–2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11(4):278–280PubMedCrossRef

29.

Rosenthal SI, Depowski PL, Sheehan CE, Ross JS (2002) Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 10(1):40–46PubMedCrossRef

30.

Cellini C, Houston TL, Martins D, Christos P, Carson J, Kemper S, Simmons RM (2005) Multiple re-excisions versus mastectomy in patients with persistent residual disease following breast conservation surgery. Am J Surg 189(6):682–686CrossRef

31.

Krecke KN, Gisvold JJ (1993) Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. Am J Roentgenol 161:957–960

32.

Le Gal M, Ollivier L, Asselain B, Meunier M, Laurent M, Vielh P, Neuenschwander S (1992) Mammographic features of 455 invasive lobular carcinomas. Radiology 185:705–708PubMed

33.

Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA, Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14(3):225–233PubMedCrossRef

Titel: Survival analysis between patients with invasive ductal and invasive lobular breast cancer
verfasst von: Darius Dian
Hannes Herold
Ioannis Mylonas
Christoph Scholz
Wolfgang Janni
Harald Sommer
Klaus Friese
Publikationsdatum: 01.01.2009
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 1/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0662-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Survival analysis between patients with invasive ductal and invasive lobular breast cancer